Mohamad Nur Afiqah, Ramachandran Vasudevan, Ismail Patimah, Mohd Isa Hazlita, Chan Yoke Mun, Ngah Nor Fariza, Md Bakri Norshakimah, Ching Siew Mooi, Hoo Fan Kee, Wan Sulaiman Wan Aliaa
Malaysian Research Institute on Ageing, Universiti Putra Malaysia, Serdang, Selangor DE 43400, Malaysia.
Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor DE 43400, Malaysia.
Int J Ophthalmol. 2017 Dec 18;10(12):1889-1897. doi: 10.18240/ijo.2017.12.16. eCollection 2017.
To describe the prevalence and changes in treatment patterns of ranibizumab and photodynamic therapy (PDT) among retinal disease patients who attended the Ophthalmology Clinic in the tertiary care Hospital Selayang from 2010 to 2014.
Study subjects were recruited retrospectively using the Electronic Medical Record (EMR) database software in Hospital Selayang. Demographic data, medical history, diagnostic procedure, treatments and diagnosis of patients were recorded.
The five-year analysis included 821 patients with a mean age of 65.9±11.73y. Overall, there were a higher number of males (63.1%) and a higher number of Chinese (47.4%) patients. Among the 821 patients, 62.9% received ranibizumab injection followed by 19.2% PDT therapy and 17.9% had ranibizumab combined with PDT therapy. Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) were the most common retinal eye diseases reported, recording prevalence of 25.0% and 45.6%, respectively. The trend in ranibizumab treatment was reported to increase while PDT showed a decrease in trend from year 2010 to 2014. In terms of treatment, following multiple logistic regression, AMD was associated with the subjects being more likely to have received ranibizumab monotherapy (<0.001) while PCV was associated with more likely to have received PDT (<0.001) and PDT combined with ranibizumab therapy (<0.001).
The tertiary care setting in Malaysia is consistent with management of patients from other countries whereby ranibizumab is the most common treatment given to patients with AMD, while PCV patients most commonly receive PDT and ranibizumab combined with PDT therapy.
描述2010年至2014年在斯里兰卡中央医院眼科门诊就诊的视网膜疾病患者中雷珠单抗和光动力疗法（PDT）的治疗模式的患病率及变化情况。
使用斯里兰卡中央医院的电子病历（EMR）数据库软件对研究对象进行回顾性招募。记录患者的人口统计学数据、病史、诊断程序、治疗和诊断情况。
五年分析纳入了821例患者，平均年龄为65.9±11.73岁。总体而言，男性患者数量较多（63.1%），华裔患者数量较多（47.4%）。在这821例患者中，62.9%接受了雷珠单抗注射，其次是19.2%接受了PDT治疗，17.9%接受了雷珠单抗联合PDT治疗。年龄相关性黄斑变性（AMD）和息肉状脉络膜血管病变（PCV）是报告的最常见的视网膜眼病，患病率分别为25.0%和45.6%。据报告，2010年至2014年期间，雷珠单抗治疗呈上升趋势，而PDT呈下降趋势。在治疗方面，经过多因素逻辑回归分析，AMD患者更有可能接受雷珠单抗单药治疗（<0.0
